AK102
Phase 3Biologic
AK102 is one of 77 biologic programs targeting Hyperlipidemia. It is currently in Phase 3.
3
Indications
8
Total Trials
0
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
130 competitors in Hypercholesterolemia
#DrugCompanyPhaseTrials
1Avapro
SanofiPhase 3
Micardis
Boehringer IngelheimPhase 3
Comparator: Statins
Merck & Co.Phase 3
Kynamro
KKastle Therapeutics, LLC
Phase 3
Enlicitide
Merck & Co.Phase 3
Anacetrapib
Merck & Co.Phase 3
Lapaquistat Acetate
TakedaPhase 3
Bococizumab
PfizerPhase 3
Lipid-Modifying Therapy (LMT)
SanofiPhase 3
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hyperlipidemia3 trials
Hypercholesterolemia2 trials
Familial Hypercholesterolemia1 trial
Safety and Efficacy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AK102. EMBL-EBI & Wellcome Sanger Institute.
- [4]